Other news WHO Pandemic Agreement talks resume Negotiations on a Pandemic Agreement have restarted in Geneva. The key topics include pandemic prevention and surveillance, the pathogen access and benefit sharing system, the legal architecture of the agreement and the One Health approach. Economic levers for addressing AMR “Antimicrobial resistance (AMR) threatens to become one of the biggest health challenges facing humanity, with devastating consequences, if humanity fails to take immediate action,” is an eye-opening introduction to this report focusing on which financial and economic levers and financing and budgeting tools can help guarantee the funding and implementation of national action plans (NAPs) on AMR. EU supports action to attract and retain nurses The Commission has agreed to support a WHO/Europe project aimed at helping member states retain nurses in their healthcare systems. The project has received a very modest he agreement, funded with €1.3 million for a three-year period. Health Commissioner Stella Kyriakides said, “Today’s action is a sign of our commitment to address the serious health workforce issues that many member states are facing.” Alcohol and breast cancer WHO and the Non-Communicable Disease (NCD) Alliance will hold a sponsored session at the World Cancer Center (WCC) on 17 September. The event will discuss data on alcohol-related cancers, with a focus on breast cancer. WHO announces first virtual mini-conference on Population Health Management WHO will host their first virtual mini-conference in their series highlighting Population Health Management (PHM) on 10-11 September. The conference will focus on discussing how “data-driven” PHM discussions can benefit primary health care (PHC) providers. WHO has identified 16 policy actions to address population health. Novo Nordisk reveals more wonders of Wegovy Novo Nordisk recently revealed new cardiovascular data at the annual congress of the European Society of Cardiology. A study, published in The Lancet, concluded that semaglutide, the active substance in Wegovy, aided in reducing the worsening of heart failure events. Another study presented evidence that semaglutide could also reduce the risk of COVID-related death by about a third in patients taking the drug compared to the ones taking the placebo. While not preventing the trial patients from getting COVID, the researchers suggested that the weight loss aided by the drug could be a potential reason for this reduced death rate. Vitestro’s autonomous blood drawing device receives CE marking Viterstro has announced that its automated blood drawing device has been approved for commercial use. This technology will provide hospitals with accurate blood draws without “manual handling”. |